+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Host factors related to poor immunogenicity of hepatitis B vaccine in adults. Another reason to immunize early



Host factors related to poor immunogenicity of hepatitis B vaccine in adults. Another reason to immunize early



JAMA 270(24): 2971-2972




(PDF emailed within 1 workday: $29.90)

Accession: 046274808

Download citation: RISBibTeXText

PMID: 8254860


Related references

Recombinant-yeast-derived hepatitis B vaccine in healthy adults: safety and two-year immunogenicity of early investigative lots of vaccine. Journal of Medical Virology 27(2): 155-159, 1989

Poor immunogenicity as the reason for the ineffectiveness of a glycoprotein subunit vaccine for genital herpes. Vaccine 7(2): 184-185, 1989

Active hepatitis b immunization with an experimental german vaccine 1. immunogenicity studies in healthy adults 2. the primary 19s and 7s responses to hepatitis b surface antigen in healthy adults 3. immunogenicity studies in hemodialysis patients. Zentralblatt fuer Bakteriologie Mikrobiologie und Hygiene Series A 257(3): 439-455, 1984

Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine 36(5): 668-674, 2018

Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age. Vaccine 33(31): 3614-3618, 2016

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. Vaccine 31(46): 5300-5305, 2014

Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines. Vaccine 15(16): 1732-1736, 1997

Active hepatitis B immunization with an experimental German vaccine. I. Immunogenicity studies in healthy adults. II. The primary 19 S and 7 S responses to HBsAg in healthy adults. III. Immunogenicity studies in hemodialysis patients. Zentralblatt für Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology 257(3): 439-455, 1984

Reactogenicity and immunogenicity of a recombinant hepatitis B vaccine compared with a plasma-derived vaccine in young adults. Postgraduate Medical Journal 63 Suppl 2: 121-123, 1987

Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults. Journal of Travel Medicine 22(2): 105-114, 2015

Safety and immunogenicity of a combined hepatitis A and hepatitis B vaccine in young healthy adults. Scandinavian Journal of Gastroenterology 31(10): 1027-1031, 1996

Reactogenicity and immunogenicity of a combined hepatitis A/hepatitis B vaccine in healthy adults. Journal of Hepatology 23(SUPPL 1): 104, 1995

Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults. Human Vaccines and Immunotherapeutics 9(11): 2474-2479, 2014

Active pre exposure immunization against hepatitis b virus immunogenicity of hepatitis b vaccine in healthy thai adults and children. Asian Pacific Journal of Allergy & Immunology 5(1): 83, 1987

The immunogenicity and impact factors of hepatitis A attenuated live vaccine and inactivated vaccine. Zhongguo Yi Miao He Mian Yi 15(4): 371-374, 2010